Close menu




January 10th, 2024 | 07:15 CET

Evotec, Defense Metals, PayPal - There is movement here. Where is it worth getting in?

  • Mining
  • RareEarths
  • Biotechnology
  • Technology
Photo credits: pixabay.com

In the dynamic environment of the stock market, it is often significant movements in individual shares that attract the attentive eye of investors. Volatile securities lure investors with the promise of quick profits, but they may signal more than just short-term market fluctuations. When stocks start to move and deviate from their usual trading patterns, it can indicate fundamental changes in the business environment, industry-specific developments or macroeconomic turning points. For the savvy investor, this might be the opportune moment when promising entry opportunities reveal themselves. However, caution is advised: Only those prepared to look behind the scenes and analyze the factors behind the volatility can truly profit from market movements.

time to read: 4 minutes | Author: Armin Schulz
ISIN: EVOTEC SE INH O.N. | DE0005664809 , DEFENSE METALS CORP. | CA2446331035 , PAYPAL HDGS INC.DL-_0001 | US70450Y1038

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Evotec - CEO resigns

    The Evotec share started to establish an upward trend in October 2023. However, the share plummeted on January 4, breaking the established trend. The reason for this was the surprising resignation of CEO Werner Lanthaler for personal reasons. As a temporary solution, Supervisory Board member Dr. Mario Polywka has taken over the position of CEO on an interim basis. It is unknown whether the resignation has anything to do with Lanthaler's delayed directors' dealings. The Company intends to automate this process in future. There were failures here that should not be repeated in the future.

    December was a promising month. The biotech company Evotec secured license fees through the approval of a sleep disorder drug from its partner, Zhejiang Jingxin Pharmaceuticals, in China. On January 8, the Company announced it would receive a milestone payment of USD 25 million from its partnership with Bristol Myers Squibb. The money will be used for further research into active substances in the field of nerve diseases. The partnership, concluded in 2016 and extended from 2023 to 2031, could total up to USD 4 billion. The milestone payment supports Evotec's annual targets and surprised analysts positively.

    Another profitable partnership could be the one with Owkin. Both companies want to accelerate the discovery and development of new therapeutics in the field of oncology and immunology with the help of AI-supported platforms. Operationally, things are going well. The penalties due to the delayed director dealings should not exceed EUR 1 million. Warburg Research has issued a "Buy" recommendation with a price target of EUR 29. Deutsche Bank and RBC Capital Markets leave the share at "Hold" with price targets between EUR 18.60 and EUR 20.00. The share is currently trading at EUR 18.10.

    Defense Metals - Feasibility study nearing completion

    The Defense Metals share was under pressure in mid-December during the tax loss season. The share then exploded upwards by over 80% within a few days. The share subsequently gave back some of its gains, but the long-undervalued stock still came into focus. The Company owns a large rare earth deposit in British Columbia, Canada. The project, known as Wicheeda, covers 6,759 hectares and has a mineral resource of 34.2 million tons of material with an average rare earth oxide (TREO) grade of 2.02%. These figures were announced in September and represent a significant increase on the previous estimate.

    The Company is currently working on the preliminary feasibility study (PFS). Phase II and III collection of all infrastructure-related geotechnical field data for the study was completed in December. CEO Craig Taylor expects the PFS to be completed in Q2. On January 9, Defense Metals announced that it has signed a Memorandum of Understanding with Ucore to collaborate on rare earths. As a first step, Ucore will receive a composite sample of rare earth carbonate from the hydrometallurgical pilot tests to test processing at a UCore facility. The CEOs of both companies emphasized the importance of cooperation between companies in North America regarding rare earths.

    Currently, the world is dependent on China for rare earths. Due to the smouldering trade dispute between the US and China, there is an urgent need to remedy this situation. Raw materials are needed in various sectors such as agriculture, healthcare, electronics, energy, aerospace, defense and the automotive industry. More rare earths are needed for electric cars in particular. It is estimated that 1-3 kg are needed per electric vehicle. With 10 million new vehicles, we are talking about 20% of current global demand. Demand will, therefore, increase. The share is currently trading at CAD 0.225. The December high was CAD 0.275.

    PayPal - The turnaround may have already begun

    In 2021, PayPal shares were already trading at over USD 309, benefiting from the coronavirus lockdown. Since then, it has fallen to USD 50.25 in October 2023. The share has been robust since the low and has formed an upward trend. Is this sustainable? The Company has long been known for steady growth and a solid business model, experiencing a share price decline due to challenges in 2022 and 2023. Nevertheless, there are signs of an imminent recovery that should make investors sit up and take notice.

    After sales declined as expected with the end of the lockdown, the wind may have turned with the Q3 figures. Turnover rose by 9% to USD 7.8 billion and surprised with positive key figures such as transactions per account or total transactions. Margins have declined due to the white-label solutions, which the management intends to compensate for with a savings program amounting to USD 900 million. Investors will find out whether the first successes are already visible on January 30, when the figures for the fourth quarter are to be published.

    Analysts expect earnings per share to increase by around 10%. Over the year as a whole, earnings per share should even rise by more than 20%. This could provide a further tailwind. The fundamental data also looks favourable for a major technology stock. The price-to-earnings ratio is below 12. The developments at PayPal are reminiscent of other tech stocks, such as Nvidia or Meta, which have shot up significantly after a deep decline. The average price target of analysts is USD 76.27. The stock is currently available for USD 61.40.


    There has been plenty of movement at all three companies recently. Nobody would have thought that the resignation of the CEO at Evotec would trigger a shortfall of over 20%. Operationally things are going well. Defense Metals has made a leap upwards. Given the progress the Company has made recently, this was overdue. Once production starts the share needs to be revalued. PayPal has suffered in recent months. A bottom now seems to have been found. Whether it will experience a comeback similar to Nvidia or Meta remains to be seen. However, the share does have upside potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET

    Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom

    • Biotechnology
    • Biotech
    • Pharma

    The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.

    Read

    Commented by Fabian Lorenz on December 10th, 2024 | 07:15 CET

    HIGHFLYER stocks with upside potential: Renk, TUI, Almonty Industries

    • Mining
    • Tungsten
    • Defense
    • Travel

    The current year has seen the beginning of a revaluation of Almonty Industries. The tungsten producer's stock has already gained more than 50%. If analysts have their way, it could gain another 250%. According to analysts, there could still be over 250% upside potential, as the Company is on the verge of a revenue and profit surge with the opening of a mega-mine. The TUI share has finally jumped above the EUR 8 mark. Driven by statements about a strong summer season in 2025, there is room for further growth. At its IPO, Renk was sold as a high-flyer in the defense sector. While the Company has yet to live up to these high expectations, analysts see over 50% price potential.

    Read

    Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET

    Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer

    • Biotech
    • Pharma
    • Biotechnology

    There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.

    Read